GLPwatch
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.
Diabetes Care · 2010
Last updated 2026-05-28In a 1-year study of 69 people with type 2 diabetes, those taking exenatide lost an average of 6% of their body weight and 13% of trunk fat. Exenatide also increased a heart-healthy protein (adiponectin) by 12% and lowered a heart-risk marker (high-sensitivity C-reactive protein) by 61%. These benefits were not linked to changes in body weight or fat.
AI summary of the abstract below.
| Journal | Diabetes Care, 2010 |
|---|---|
| Citations | 130 |
| Relative citation ratio | 3.48 |
| NIH percentile | 87 |
| Molecules | exenatide |
| Conditions studied | Cardiovascular Risk Reduction |
Abstract
OBJECTIVE: To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers.
RESEARCH DESIGN AND METHODS: Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured.
RESULTS: Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively. In addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive protein by 61%. Insulin glargine significantly reduced endothelin-1 by 7%. These changes were statistically independent of the change in total body fat mass and body weight.
CONCLUSIONS: Exenatide treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with insulin glargine except a trend for reduced endothelin-1 levels.
Verbatim abstract via PubMed 20424219 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.